At a glance
- Originator Abbott Laboratories
- Class Antiasthmatics
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Oct 1997 No-Development-Reported for Cancer in USA (Unknown route)
- 17 Mar 1995 New profile
- 16 Mar 1995 Preclinical development for Cancer in USA (Unknown route)